此次百克生物的调价并非突发，而是其市场策略调整的延续。公开信息显示，早在2025年上半年，公司 就已通过惠民活动推出3—8折的折扣政策，彼时部分产品实际售价已显著偏离官方定价。而此次针对江 西省的官方调价，标志着其降价策略正式从阶段性促销转向常态化定价调整。 百克生物向《华夏时报》记者进一步解释，此次价格调整的核心目标，是通过建立更可持续的定价机 制，切实减轻大众尤其是中老年群体的接种经济负担，从而推动疫苗更广泛地覆盖目标人群，同时提升 疫苗可及性与渗透率，激活潜在市场需求。 本报（chinatimes.net.cn）记者王瑜 于娜 北京报道 年末，国产疫苗市场迎来重磅调价。 近日，江西省疾控中心发布公示显示，长春百克生物科技股份公司（下称"百克生物"，688276.SH）正 式递交调价函，将其核心产品——带状疱疹减毒活疫苗（规格：0.5ml，商品名：感维）的采购价（含 配送费）从原1375元/支大幅下调至464元/支，单支降价911元，降幅接近70%。 百克生物董秘办在接受《华夏时报》记者采访时明确表示："此次调价将切实降低民众接种成本，有助 于提升该疫苗在我国的可及性和渗透率，并进一步激发市场需求的释放。 ...

（文章来源：证券日报） 证券日报网讯 1月9日，百克生物在互动平台回答投资者提问时表示，公司在研的阿尔茨海默病治疗性 疫苗，以国际上广泛认可的靶向Aβ和Tau蛋白进行抗原设计，旨在诱导机体产生针对Aβ和Tau的抗体， 以清除脑内产生的病理性Aβ和Tau蛋白，从而延缓疾病的进展。该项目正处于临床前研究阶段。 ...

金鹰鑫瑞混合A（003502）基金经理为倪超、龙悦芳。 截至发稿，倪超累计任职时间10年215天，现任基金资产总规模31.84亿元，任职期间最佳基金回报 156.51%， 任职期间最差基金回报-22.26%。 龙悦芳累计任职时间8年125天，现任基金资产总规模96.07亿元，任职期间最佳基金回报41.61%， 任职 期间最差基金回报-1.52%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月8日，百克生物涨5.03%，截至发稿，报20.47元/股，成交7486.62万元，换手率0.91%，总市值84.68 亿元。 资料显示，长春百克生物科技股份公司位于吉林省长春市朝阳区卓越大街138号，成立日期2004年3月4 日，上市日期2021年6月25日，公司主营业务涉及从事人用疫苗的研发、生产和销售。主营业务收入构 成为：水痘疫苗116.82%，流感疫苗6.07%。 从基金十大重仓股角度 数据显示，金鹰基金旗下1只基金重仓百克生物。金鹰鑫瑞混合A（003502）三季度持有 ...

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

Core Viewpoint - The price of the domestic varicella-zoster vaccine is being gradually reduced, with a significant price drop of over 66% from 1375 yuan to 464 yuan per dose, which may impact the company's revenue and market dynamics [1][2]. Group 1: Vaccine Pricing and Market Dynamics - Changchun Baike Biological Technology Co., Ltd. has adjusted the price of its varicella-zoster vaccine, reflecting a broader trend of price reductions in the industry to enhance public awareness and accessibility [1]. - The company has previously implemented discount pricing strategies, leading to reduced revenue and increased pressure on its financial performance [1][2]. - The global market features four varicella-zoster vaccines, with only two available in China, indicating a competitive landscape that may influence pricing strategies [1][9]. Group 2: Industry Challenges and Opportunities - The vaccine industry faces challenges such as competition, vaccine hesitancy, and consumer confidence, but long-term growth potential remains due to the low market penetration compared to developed countries [2]. - Public awareness of varicella-zoster disease is low, with a significant portion of the population unaware of the disease, which affects vaccination rates [4][5]. - A study indicated that the vaccination rate among adults aged 40 and older in China is only 0.79%, highlighting a significant opportunity for growth in the market [5]. Group 3: Financial Performance and Sales Trends - In 2023, the company produced 1.3512 million doses of the varicella-zoster vaccine, generating 880 million yuan in revenue, which was a key driver for a 70.3% increase in overall revenue [5]. - However, in 2024, revenue from the vaccine is projected to decline by 71.54% to 251 million yuan, with a significant drop in sales volume and an increase in inventory [5][6]. - The company's financial performance has shown a downward trend, with a 32.64% decrease in revenue and a 53.67% drop in net profit in 2024 compared to the previous year [6][7]. Group 4: Competitive Landscape and Future Strategies - The varicella-zoster vaccine market is becoming increasingly competitive, with GSK's vaccine still holding a significant market share despite a decrease in production [9][10]. - The company plans to enhance vaccine accessibility by integrating vaccination services with clinical medical systems and correcting public misconceptions about the disease [10]. - Baike Biological is also focusing on other vaccine projects, with ongoing clinical trials and new product developments aimed at diversifying its portfolio and improving market position [10].

证券日报网讯12月25日，百克生物发布公告称，因朱绍辉工作调整，中信证券委派范新亮接替其担任持 续督导保荐代表人，与王晨晨共同履职，督导期延续至募集资金使用完毕。 ...

Core Viewpoint - The price reduction of the varicella-zoster vaccine by Baike Biotech has drawn public attention, with the procurement price dropping from 1375 yuan to 464 yuan, a decrease of approximately 66% [1][4]. Group 1: Vaccine Pricing and Market Dynamics - Baike Biotech's varicella-zoster vaccine, which is a live attenuated vaccine, has seen its price significantly reduced, making it more accessible compared to the imported vaccine "Shingrix," which is priced around 1650 yuan even with promotional offers [4][5]. - The imported vaccine "Shingrix" has been offering a "buy one get one free" promotion since Q2 2023, but the total cost remains high compared to the newly priced domestic vaccine [5][10]. - The price reduction aims to enhance vaccination rates among the elderly population, who have shown low willingness to get vaccinated due to high costs and lack of awareness about the disease [7][8]. Group 2: Market Potential and Industry Challenges - The varicella-zoster vaccine market in China is still in its early stages, with only two vaccines currently available: the imported "Shingrix" and Baike Biotech's domestic vaccine [4][10]. - Despite the price drop, Baike Biotech reported a significant decline in revenue, with a 53.8% year-on-year decrease in revenue to 470 million yuan and a net loss of 160 million yuan in the first three quarters of the year [10][11]. - The company is focusing on increasing public awareness and accessibility of the vaccine through promotional activities and partnerships with healthcare providers to improve market penetration [11].

证券代码：688276 证券简称：百克生物 公告编号：2025-045 公司董事会对朱绍辉先生在公司首次公开发行股票并在科创板上市及持续 督导期间做出的贡献表示衷心的感谢！ 特此公告。 长春百克生物科技股份公司董事会 2025 年 12 月 26 日 1 长春百克生物科技股份公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 长春百克生物科技股份公司（以下简称"公司"或"百克生物"）于近日收 到中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）出具的《关 于更换保荐代表人的函》。原保荐代表人朱绍辉先生因工作调整，不再继续担任 公司持续督导的保荐代表人。为保证公司持续督导工作的有序进行，中信证券现 委派范新亮先生（简历附后）接替朱绍辉先生担任公司持续督导的保荐代表人， 继续履行持续督导职责。 本次保荐代表人变更后，公司首发上市项目持续督导期间的保荐代表人为王 晨晨先生、范新亮先生。公司首次公开发行股票的持续督导期已于 2024 年 12 月 31 日届满，由于公司募集资金尚未使用完 ...

Core Viewpoint - The price of the varicella-zoster virus vaccine produced by Changchun Baike Biotechnology Co., Ltd. has been reduced by approximately 66%, from 1375 yuan to 464 yuan per dose, aiming to increase vaccination rates among the elderly population [1][4]. Company Summary - Changchun Baike Biotechnology is the only domestic company with a varicella-zoster vaccine currently on the market, and its stock price is 19.19 yuan with a market capitalization of 7.938 billion yuan [1]. - The company reported a significant decline in revenue, with a 53.8% year-on-year decrease to 470 million yuan in the first three quarters, and a net loss of 160 million yuan, primarily due to product returns and price reductions [10][11]. - The company has initiated a discount pricing strategy to enhance public awareness and accessibility of the vaccine, aiming to improve market penetration and correct misconceptions about the disease [11]. Industry Summary - The varicella-zoster vaccine market in China is still in its early stages, having transitioned from a nascent phase (2019-2022) to a growth phase in 2023 with the introduction of domestic vaccines [4]. - The market currently has low penetration rates, with vaccination rates for the varicella-zoster vaccine among the target population being less than 1% [7]. - The competitive landscape is not yet clearly defined, with few domestic players involved, including Baike Biotechnology and others [10]. - The imported vaccine "Shingrix" has also been active in the market, offering promotions such as "buy one, get one free," but remains significantly more expensive than the newly priced domestic vaccine [4][5].

一款曾被寄予厚望的疫苗，上市两年多后价格腰斩再打折，甚至让公司季度财报上出现负收入和负销量，股价随之跌跌不休。 12月23日，江西省疾控预防中心网站显示，长春百克生物科技股份公司（下称"百克生物"，证券代码：688276）递交调价函，将带状疱疹减毒活疫苗（规 格：0.5ml）价格从原采购价（含配送费）1375元/支降至464元/支，即一针降价911元，价格下调约66.25%。 | 序号 | 疫苗名称 | 规格 | 剂型 | 包装 | 最小包 | 生产企业 | 原采购价格含配送 | 调整后采购价含配 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 装单位 | | 费(元/支) | 送费(元/支) | | | 带状疱疹减毒 | 0.5m1 | 注射 | 预填 | ত তেওঁ | 长春百克生物 | 1375.00 | 464.00 | | | 活疫苗 | | 쥐 | 车 | | 科技股份公司 | | | 目前，中国共有两款带状疱疹疫苗获批，一款是 葛兰素史克 ( GSK )研发生产的Shingrix，该疫苗于2020年6月 ...